Table 2.
Patient ID | Gender | Age at study, y | HLA DQ2/DQ8 | Antigliadin IgA and/or IgG | Anti-TG6 IgA and/or IgG | PC stained | GL stained |
---|---|---|---|---|---|---|---|
8 | M | 33 | DQ2 | IgA | + | ||
9a | M | 41 | + | ||||
20 | M | 50 | DQ8 | + | ++ | ||
27 | M | 67 | ++ | ||||
28 | M | 56 | IgA | + | + | ||
30a | M | 46 | + | ||||
31 | M | 50 | ++ | + | |||
32 | M | 66 | IgA | ++ | + | ||
33 | M | 58 | DQ8 | ||||
37 | M | 53 | DQ2 | IgA | + | ||
38 | F | 56 | IgA | + | |||
45 | M | 49 | DQ8 | + | |||
47 | F | 60 | IgA | ||||
49a | M | 51 | DQ8 | IgA, IgG | IgA | ||
55 | F | 48 | DQ2 | + | |||
62 | M | 41 | |||||
69 | M | 58 | |||||
92 | M | 64 | DQ8 | ++ | + | ||
100 | M | 55 | DQ2 | IgA | |||
101 | F | 49 | DQ2 | + | |||
103 | F | 48 | DQ8 | IgA | + | ||
104 | M | 55 | DQ2 | + | |||
107a | M | 46 | DQ2 | IgA | IgA | ++ | ++ |
116 | M | 51 | DQ8 | IgG | ++ | ||
119 | M | 48 | IgA | ++ | |||
120a | M | 50 | IgA | + | |||
121 | M | 45 | + | ||||
122a | M | 50 | IgA | IgA | + | ||
125 | F | 66 | DQ2 | IgA | |||
128 | M | 68 | DQ2 | IgA | |||
132 | M | 62 | |||||
133a | M | 59 | DQ2 | IgA | IgA | + | ++ |
134 | F | 58 | + | ||||
135 | M | 57 | IgA | IgA | + | ||
136a | M | 47 | IgA | IgA | + | ||
139 | M | 65 | DQ2 | IgA, IgG | IgA, IgG | ||
143 | M | 67 | IgG | ||||
145 | M | 81 | + |
asubgroup chronic liver disease and ataxia (CLDA), y years, TG6 transglutaminase 6, PC Purkinje cell layer, GL granular layer, + weak staining, ++ strong staining